ESMO Targeted Anticancer Therapies Congress 2023
Promising results for an FGFR 1–3 inhibitor in molecularly altered tumours
CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies
Encouraging results validate PARP7 and TGFβ1 as potential targets for immunotherapy
Safety and biomarker status data of the PARP7 inhibitor RBN-2397 and the IgG4 monoclonal antibody SRK-181 presented at the ESMO TAT Congress 2023
New tools and methods are discussed for optimising investigation of precision therapeutics
Results of extensive genomic profiling and a Time-to-Event Continual Reassessment Method show some promise in investigating new treatments and targets in early-phase trials, despite not being ready for routine research
NGS – a weapon in molecular pathology?
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed
Early phase cancer research – ready for a change?
New recommendations of the MDICT Taskforce highlight the need to rethink how research studies are conducted and of multi-stakeholder collaboration
Improving collaboration to expedite early-phase research in oncology
Among all the stakeholders involved, oncology societies can play a pivotal role to facilitate efficient clinical investigations
Epigenetic therapies – have they come of age?
The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies